Financials in USD. Standardized financial statements.
A compact view of how Lifecore Biomedical, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $128.87M | $128.26M | $103.27M | $111.27M | $100.87M | $160.07M | $557.56M | $524.23M | $532.26M | $541.10M |
| Revenue Growth? | +0.5% | +24.2% | -7.2% | +10.3% | -37.0% | -71.3% | +6.4% | -1.5% | -1.6% | 0.0% |
| Cost of Revenue? | $88.57M | $86.41M | $75.28M | $72.20M | $61.94M | $120.68M | $476.56M | $445.89M | $449.07M | $470.14M |
| Gross Profit? | $40.30M | $41.85M | $27.98M | $39.07M | $38.94M | $39.39M | $81.00M | $78.34M | $83.19M | $70.96M |
| Gross Margin? | +31.3% | +32.6% | +27.1% | +35.1% | +38.6% | +24.6% | +14.5% | +14.9% | +15.6% | +13.1% |
| Operating Expenses? | $57.54M | $50.69M | $49.78M | $50.86M | $47.76M | $65.26M | $75.53M | $64.75M | $67.68M | $56.74M |
| Operating Income? | -$17.25M | -$8.84M | -$21.80M | -$11.79M | -$8.82M | -$25.88M | -$8.01M | $11.85M | $15.51M | -$19.79M |
| EBITDA? | -$8.81M | $35.60M | -$33.17M | $12.84M | -$987,000 | -$7.16M | $23.47M | $24.99M | $26.68M | -$7.80M |
| Income Before Tax | -$38.67M | $9.51M | -$63.93M | -$20.69M | -$29.79M | -$30.64M | $3.64M | $16.40M | $15.01M | -$18.85M |
| Income Tax Expense | $43,000 | $183,000 | $308,000 | -$5.21M | -$6.35M | -$8.77M | $1.52M | -$9.36M | $4.33M | -$7.40M |
| Net Income? | -$38.72M | $12.01M | -$99.56M | -$116.72M | -$32.29M | -$38.19M | $2.12M | $24.83M | $10.59M | -$11.64M |
| EPS? | $-1.27 | $0.39 | $-3.32 | $-3.97 | $-1.12 | $-1.31 | $0.07 | $0.90 | $0.39 | $-0.43 |
| Diluted EPS? | $-1.27 | $0.33 | $-3.32 | $-3.97 | $-1.12 | $-1.31 | $0.07 | $0.89 | $0.38 | $-0.43 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality